



**Prostatype Genomics AB**

Org. 556726-0285

**Quarterly report Q2 2023**

1 April 2023 – 30 June 2023

---

Prostatype Genomics AB | 556726-0285 |  
[www.prostatypegenomics.com](http://www.prostatypegenomics.com)

## Quarter 2 (1 April – 30 June 2023) summarized

- Net sales amounted to 56 TSEK.
- Net revenue amounted to 56 TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -9 587 TSEK.
- Cash flow from current operations in the quarter amounted -11 061 TSEK.
- Total cash flow for the period amounted to 9 523 TSEK.
- Earnings per share amounted to -0,08 SEK.

## Period 1 Jan – 30 June 2023 summarized

- Net sales amounted to 447 TSEK.
- Net revenue amounted to 447 TSEK.
- EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -11 937 TSEK.
- Cash flow from current operations in the quarter amounted -20 338 TSEK.
- Total cash flow for the period amounted to 205 TSEK.
- Earnings per share amounted to -0,15 SEK.



## Significant events during the second quarter

### The company conducts Annual General Meeting

On June 1, 2023, the Annual General Meeting for the financial year 2022 was held.

The Annual General Meeting adopted the income statements and balance sheets for the financial year 2022 and resolved, in accordance with the Board's proposal, that the profit according to the adopted income statement would be carried forward. No dividend will be paid.

The Annual General Meeting resolved, for the period until the end of the next Annual General Meeting, to re-elect Anders Lundberg, Michael Häggman, Håkan Englund and Mattias Prage as Board members. Furthermore, Henrik Nilsson was elected as a new board member. Karlheinz Schmelig was not available for re-election. The Annual General Meeting resolved to appoint Anders Lundberg as Chairman of the Board.

### Outcome of Rights issue

On 16 May 2023, the Company announced the outcome of the new issue of shares with preferential rights for the Company's shareholders (the "Rights Issue"), the subscription period of which ended on 11 May 2023. The subscription summary shows that 77,226,496 shares, corresponding to approximately 56.3 percent of the Rights Issue, were subscribed for with or without subscription rights, of which 71,151,384 shares, corresponding to approximately 51.9 percent of the Rights Issue, were subscribed for with subscription rights and 6,075,112 shares, corresponding to approximately 4.4 percent of the Rights Issue, were subscribed for without subscription rights. Accordingly, the guarantors were allocated approximately 13.7 percent of the Rights Issue, whereby the Rights Issue was subscribed for approximately 70 percent in total and Prostatype Genomics was thereby provided with approximately SEK 24.0 million before issue costs.

### Prostatype Genomics appoints Professor Gerald Andriole as Chief Medical Officer

Prostatype Genomics AB announced on May 5, 2023, that Professor Gerald Andriole has been appointed Global Chief Medical Officer at Prostatype Genomics. With more than 35 years of experience in urology, Professor Andriole brings experience and expertise to Prostatype Genomics' efforts to commercialize the Prostatype® test in the U.S. and globally.

Gerald L. Andriole, Jr., MD, comes from the post of professor in the Department of Urology and director of the Brady Urological Institute in the National Capital Region at Johns Hopkins University. Prior to that, he was professor and director of urological surgery at Barnes-Jewish Hospital, Siteman Cancer Center, and Washington University School of Medicine in St. Louis, Missouri.

Professor Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and completed urology training at Brigham and Women's Hospital and Harvard Medical School, Boston, MA. He then received specialist training in urological oncology at the National Cancer Institute in Bethesda, Maryland.

### **The company publishes prospectus in connection with rights issue**

On April 24, the Company announced that the Swedish Financial Supervisory Authority has approved the prospectus prepared by Prostatype Genomics in connection with the upcoming rights issue has been approved and registered by the Swedish Financial Supervisory Authority.

### **The company conducts an extraordinary general meeting**

On April 21, Prostatype Genomics AB held an extraordinary general meeting where the following was resolved.

In accordance with previously published information, the Board of Directors resolved on 22 March 2023 on a rights issue, subject to the subsequent approval of the Extraordinary General Meeting.

### **Outcome of Warrants Series TO 2**

On March 30, 2023, the exercise period for Prostatype Genomics AB's warrants of series TO 2 ended. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to SEK 7,603.80.

During the period 9-30 March 2023, holders of warrants of series TO 2 had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 2 entitled the holder to subscribe for one (1) new share in Prostatype Genomics at a subscription price set at SEK 2.90. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to a subscription of SEK 7,603.80. The utilization entails a dilution of 0.01 percent.

## **Significant events during the first quarter**

### **Prostatype Genomics initiates collaboration with Spanish Eurofins Megalab**

In March, it was announced that Prostatype Genomics is entering into collaboration with Eurofins Megalab, a leader in clinical analysis in the Spanish laboratory market and part of Eurofins, one of the world's largest laboratory groups with operations in Europe, the US, Asia, and Latin America. The agreement means that Eurofins Megalab will handle all steps of the laboratory process required to analyse the Prostatype® test on the Spanish and Portuguese markets. The collaboration is another step in Prostatype Genomics' work to further accelerate commercialization in Europe. The agreement will enter into force immediately.

## Study with Prostatype® published in leading international journal

The study, conducted by a research team at Uppsala University Hospital led by associate professor and chief physician Michael Häggman, shows that the Prostatype® gene test correctly assesses the aggressiveness of the prostate cancer tumour when comparing gene expression from tissue samples, so-called biopsies, with the "result", i.e., the operated prostate (radical prostatectomy). The study is now published in *The Prostate*, a leading peer reviewed publication aimed at, among others, urologists, and pathologists.

## Resolution on extraordinary general meeting and rights issue

In March, the Board of Directors announced that it convened an extraordinary general meeting to approve a new issue of shares of approximately SEK 34.3 million with preferential rights for existing shareholders.

## Prostatype Genomics recruits Steven Gaal as President of Prostatype Genomics Inc., USA

Prostatype Genomics AB has recruited Steven Gaal to the role of President of the company's wholly owned subsidiary, Prostatype Genomics Inc. Stevens' task will be to establish and launch Prostatype®, the company's gene test for assessing the aggressiveness of prostate cancer in patients, on the US market. Steve has over 18 years of experience from leadership positions in sales of cancer diagnostic tools and services and will join Prostatype Genomics Inc. with immediate effect.

Steven joins Prostatype Genomics Inc. with extensive experience in genomic testing. Steven has experience working in both start-ups and more established companies. He has held senior positions at USLABS (acquired by LabCorp), P4Diagnostix and most recently SkylineDx. As Sales Director at MDxHealth, Steven was instrumental in launching ConfirmMDx for prostate cancer and SelectMDx for prostate cancer to US-based urologists.

## Prostatype Genomics AB enters into agreement with Life Genomics AB

Prostatype Genomics and Life Genomics are entering into a non-exclusive collaboration whereby Life Genomics will handle all steps in the laboratory process required to analyze Prostatype, the Prostatype® Genomics gene test to assess the aggressiveness of prostate cancer. The collaboration means that Prostatype Genomics can further focus on marketing the test to patients and doctors and secures resources to be able to handle the increased demand for Prostatype® from patients and healthcare. The agreement applies to all Nordic countries and enters into force immediately.

The collaboration means that Life Genomics will handle the entire process from receiving referrals from healthcare providers to performing and reporting the results of the gene analysis in accordance with Prostatype Genomics' quality-assured processes.

## CEO comments

The second quarter of the year saw continued strong investment in a rapid US launch in parallel with several important steps being taken towards a broader commercial presence in several of our prioritized European markets. After sales growth for several quarters in a row, Q2 fell out a little lower, which is explained by timing factors as several buy orders came in right at the beginning of Q3. Consequently, we already know that Q3 will perform significantly better and be more in line with the sales growth we have seen over the past year. Although we are not yet quite where we want to be, the trend in sales growth remains positive, which of course is pleasing.

With the recruitment of Steve Gaal as President and responsible for our US subsidiary, we have established the necessary conditions for the communication with authorities required for our entry into the US market to be as fast, cost-effective, and affordable as possible. This work has accelerated during the quarter where we had initial meetings with Medicare, which is the part of the US healthcare market that determines whether a product should be included in the public US reimbursement system or not. There have been very rewarding meetings with quick and concrete feedback on how Prostatype Genomics should best act to be covered by Medicare's reimbursement system. Unlike in Europe, we have the advantage of not being the first on the US market as other companies that provide similar tests as Prostatype® have made the journey before us. Our strategy is not to do anything different or special in relation to our competitors, but to follow the practices and arrangements that have proven to work historically to ensure that Prostatype® will replace the patients who use the product as soon as possible.

The discussions have initially been conducted at a high scientific level and it has been crucial to have the support of Professor Gerald Andriole, who last spring was appointed Chief Medical Officer of Prostatype Genomics both in the US and globally. The respect that Professor Andriole enjoys in the US as both a clinician and a researcher means a lot for the future growth of Prostatype Genomics in that market. With over 35 years of experience from leading US institutions in urology, and with over 450 peer-reviewed publications, Professor Andreoli gives some weight when discussing with US authorities, to say the least.

In summary, it is full steam ahead in the United States, with ongoing discussions with both authorities and commercial partners, while we participate in the important urological congresses that are regularly held around the country. As I write these lines, I have just returned to Sweden after representing Prostatype Genomics at a urology congress in the United States. We continue to build up our network of leading American urologists, including the first American advisory board meeting regarding Prostatype® with several of America's leading urologists present. Their feedback is and will be invaluable to us in the future, as the urologists who participated in the meeting have extensive experience of using biomarkers similar to Prostatype®.

The next concrete step in Prostatype Genomics' US establishment will be to conclude already initiated negotiations with a suitable laboratory partner in the US (so-called CLIA partner), which is a piece of the puzzle that needs to be in place from Medicare's point of view. We are still in several interesting discussions and hope to be able to reach an agreement with the right partner in the coming quarters. As I previously mentioned, the decision regarding the selection of CLIA partners is a crucial milestone for the company, which is why the board and management need to carefully evaluate the options available from both a short- and long-term perspective.

In our prioritized markets in Europe, we are beginning to see that the great interest many hospitals and laboratories have shown in Prostatype® has turned into concrete measures. During the spring, we initiated studies with leading players in several markets, including Italy and Spain, while deepening our collaborations with major laboratory partners. One example of this is that Emilie Berglund, Chief Technology Officer at Prostatype Genomics, recently carried out certifications on site at several laboratories around Europe, which can now perform the entire process of sampling and analysis in a quality-assured manner. This is fully in line with our strategy to work with leading partners in prioritized markets, thus enabling rapid expansion as cost-effectively as possible.

Finally, we continue to work tirelessly to continue to strengthen our scientific footprint in the form of several ongoing validation studies with Prostatype® both in the US and Europe. We eagerly await the outcome of these studies and even though validation studies can be described more as marketing activities and are not conducted to investigate whether the product works or not, it was both gratifying and interesting that one of America's leading urologists at the conclusion of the recently held congress stood up in front of his colleagues and stated that "The Prostatype® data is very impressive"!

Thank you for joining us on the journey, and please keep an eye on our website, [www.prostatypegenomics.com](http://www.prostatypegenomics.com) and take part of our exciting news in the future!

**Fredrik Persson**

**CEO Prostatype Genomics AB**

**Solna 17 August 2023**

## Financial information and comments

### Comparison between March-June 2023 and March-June 2022

#### Net sales

Net sales for the Company amounted to 56 (8) TSEK. The company is still in the initial phase of commercialization; hence sales are as expected.

#### Operating profit/loss

The operation profit/loss for the Company's second quarter 2023 amounted to -10 057 (-7 373) TSEK which is a decrease with approximately 27 % in comparison to prior period. The company's costs consist mainly of commercialization, testing and staff.

#### Cash flow from current operations

The cash flow for the second quarter amounted to 9 523 (- 8 189) TSEK. The cash flow from current operations amounted to -11 061 (-8 289) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to 5 (0) TSEK. From the start of 2022 all product development is carried as expense.

#### Cash flow from financing activities

The cash flow from financing activities amounted 20 579 (-100) TSEK. Liquid funds as of 30<sup>th</sup> June 2023 amounted to 11 695 (8 811) TSEK.

#### Number of shares

On June 30<sup>th</sup>, 2023, the number of shares 119 460 007 (15 103 602). The nominal increase is assignable to share issues carried through 2023. Average amount of shares during the second quarter 2023 was 71 239 688.

### Comparison between Jan-June 2023 and Jan-June 2022

#### Net sales

Net sales for the Company amounted to 447 (269) TSEK. The company is still in the initial phase of commercialization; hence sales are as expected.

#### Operating profit/loss

The operation profit/loss for the period amounted to -17 850 (-12 910) TSEK which is a decrease with approximately 28 % in comparison to prior period. The company's costs consist mainly of commercialization, testing and staff.

#### Cash flow from current operations

The cash flow for the period amounted to 206 (-11 518) TSEK. The cash flow from current operations amounted to -20 338 (-11 318) TSEK. The cash flow for the period is in line with the Company's operating expenses.

#### Cash flow from investment activities

The cash flow from investment activities amounted to 64 (0) TSEK. From the start of 2022 all product development is carried as expense.

#### Cash flow from financing activities

The cash flow from financing activities amounted 20 479 (-200) TSEK. Liquid funds as of 30<sup>th</sup> June 2023 amounted to 11 695 (8 811) TSEK.

#### Number of shares

On June 30<sup>th</sup>, 2023, the number of shares 119 460 007 (15 103 602). The nominal increase is assignable to share issues carried through 2023. Average amount of shares during the second quarter 2023 was 71 239 688.



## Prostatype Genomics business and financial ratios

Amounts in SEK	2023-04-01	2022-04-01	2023-01-01	2022-01-01	2022-01-01
	2023-06-30	2022-03-30	2023-06-30	2022-06-30	2022-12-31
Operating margin	neg	neg	neg	neg	neg
Profit margin	neg	neg	neg	neg	neg
Return on equity	neg	neg	neg	neg	neg
Equity/debt ratio	77%	81%	84%	85%	84%
Equity captial	28 935 330	22 961 943	28 935 330	28 290 359	26 151 033
Cash flow	9 523 297	-8 189 304	292 330	-8 204 523	-8 840 443
Number of shares (end of the period)	119 460 007	15 088 761	119 460 007	15 103 602	22 859 497
Number of shares (average for the period)	71 239 688	15 096 182	71 239 688	15 096 182	18 974 129
Number of shares - full dilution (end of the period)	119 619 878	15 248 632	119 619 878	15 145 458	23 019 368
Earnings per share	-0,08	-0,49	-0,15	-0,49	1,27
Diluted earnings per share (end of the period)	-0,08	-0,48	-0,15	-0,48	1,26
Number of employees (end of the period)	6	4	6	4	6
Dividend per share	-	-	-	-	-

### Definition of key ratios

Operating margin	Operating profit/loss after depreciation /net sales
Profit margin	Net profit/loss for the year / net sales
Return on equity	Profit/loss before tax / adjusted equity
Equity/debt ratio	Adjusted equity / total assets
Earnings per share	Net profit/loss for the year / number of shares by period closing
Diluted earnings per share (end of the period)	Net profit/loss for the year / (number of shares + warrants by period closing)

## Financial statement

Amounts in SEK	2023-04-01	2022-04-01	2023-01-01	2022-01-01	2022-01-01
	2023-06-30	2022-06-30	2023-06-30	2022-06-30	2022-12-31
Net sales	55 682	7 960	447 369	268 720	682 798
Own work capitalized	-	-	-	-	-
Other operating income	-	-	-	-	-
<b>Total revenue</b>	<b>55 682</b>	<b>7 960</b>	<b>447 369</b>	<b>268 720</b>	<b>682 798</b>
<b>Operating expenses</b>					
Research and development cost	-1 520 969	-727 653	-2 051 244	-1 401 100	-3 507 690
Other external cost	-4 472 719	-3 867 915	-8 375 365	-6 376 765	-13 488 884
Staff cost	-3 633 101	-2 283 844	-6 912 172	-4 416 141	-10 388 148
Depreciation, amortization and impairment	-469 265	-486 277	-938 531	-972 559	-1 904 302
Other operating expenses	-16 345	-14 924	-20 169	-11 938	-84 067
<b>Operating profit/loss</b>	<b>-10 056 716</b>	<b>-7 372 652</b>	<b>-17 850 112</b>	<b>-12 909 784</b>	<b>-28 690 293</b>
<b>Income after financial items</b>					
Interest expenses and similar items	45	-	45	-	-
Interest expenses and similar items	-28 003	-16 177	-44 750	-34 114	-396 240
<b>Profit/loss after financial items</b>	<b>-10 084 674</b>	<b>-7 388 829</b>	<b>-17 894 817</b>	<b>-12 943 897</b>	<b>-29 086 533</b>
<b>Profit or loss before tax</b>	<b>-10 084 674</b>	<b>-7 388 829</b>	<b>-17 894 817</b>	<b>-12 943 897</b>	<b>-29 086 533</b>
<b>Total profit/loss for the period</b>	<b>-10 084 674</b>	<b>-7 388 829</b>	<b>-17 894 817</b>	<b>-12 943 897</b>	<b>-29 086 533</b>

## Balance sheet

(SEK)	2023-03-31	2022-03-31	2022-12-31
<b>ASSETS</b>			
<b>Fixed assets</b>			
<i>Intangible assets</i>			
Capitalized development expenditure	15 781 406	17 638 042	16 709 726
Patent	-	-	-
<b>Total intangible assets</b>	<b>15 781 406</b>	<b>17 638 042</b>	<b>16 709 726</b>
<i>Property, plant and equipment</i>			
Plant and machinery	-	-	-
Equipment and tools	68 404	7 026	3 599
<b>Total property, plant and equipment</b>	<b>68 404</b>	<b>7 026</b>	<b>3 599</b>
<i>Financial assets</i>			
Other financial assets	72 400	-	68 136
<b>Total financial assets</b>	<b>72 400</b>	<b>-</b>	<b>68 136</b>
<b>Total fixed assets</b>	<b>15 922 210</b>	<b>17 645 068</b>	<b>16 781 461</b>
<b>Current assets</b>			
<i>Inventory</i>			
Finished products	155 000	74 240	43 800
Advances to suppliers	138 486	74 506	138 486
<b>Total current assets</b>	<b>293 486</b>	<b>148 746</b>	<b>182 286</b>
<i>Long-term receivables</i>			
Receivables from group companies	3 725 792	-	-
<b>Total long-term receivables</b>	<b>3 725 792</b>	<b>-</b>	<b>-</b>
<i>Current receivables</i>			
Accounts receivable	627 336	396 136	502 434
Other receivables	2 133 854	1 151 756	1 655 830
Prepaid expenses and accrued income	362 933	358 480	339 464
<b>Total current receivables</b>	<b>3 124 123</b>	<b>1 906 372</b>	<b>2 497 728</b>
<i>Short-term investments</i>			
Other short-term investments		8 000 000	6 677 581
<b>Total short-term investments</b>	<b></b>	<b>8 000 000</b>	<b>6 677 581</b>
<i>Cash and bank</i>			
	11 694 704	811 439	4 811 151
<b>Total current assets</b>	<b>18 838 105</b>	<b>10 866 557</b>	<b>14 168 746</b>
<b>TOTAL ASSETS</b>	<b>34 760 315</b>	<b>28 511 625</b>	<b>30 950 207</b>

## Balance sheet

(SEK)	2023-06-30	2022-06-30	2022-12-31
<b>EQUITY AND LIABILITIES</b>			
<b>Total equity</b>			
<b>Restricted equity</b>			
Share capital	7 167 600	905 326	1 371 569
Development fund	15 781 407	18 566 363	16 709 726
<b>Total restricted equity</b>	<b>22 949 007</b>	<b>19 471 689</b>	<b>18 081 295</b>
<b>Non-restricted equity</b>			
Share premium reserve	164 201 465	130 452 900	149 318 381
Profit/loss brought forward	-140 320 325	-114 018 748	-112 162 111
Net profit/loss for the year	-17 894 817	-12 943 897	-29 086 533
<b>Total non-restricted equity</b>	<b>5 986 322</b>	<b>3 490 254</b>	<b>8 069 738</b>
<b>Total equity</b>	<b>28 935 330</b>	<b>22 961 943</b>	<b>26 151 033</b>
<b>Long-term liabilities</b>			
Convertible loan	-	-	-
Other debt to credit institutions	266 417	866 667	466 667
<b>Total long-term liabilities</b>	<b>266 417</b>	<b>866 667</b>	<b>466 667</b>
<b>Current liabilities</b>			
Debt to credit institutions	400 000	200 000	400 000
Accounts payable	2 870 597	2 510 290	2 183 975
Tax liabilities	150 707	141 009	240 286
Other current liabilities	431 323	255 471	461 364
Accrued liabilities and deferred income	1 705 941	1 576 244	1 046 881
<b>Total current assets</b>	<b>5 558 567</b>	<b>4 683 014</b>	<b>4 332 506</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>34 760 315</b>	<b>28 511 625</b>	<b>30 950 207</b>

## Cash flow statement

(SEK)	2023-04-01	2022-04-01	2023-01-01	2022-01-01	2022-01-01
	2023-06-30	2022-06-30	2023-06-30	2022-06-30	2022-12-31
<b>Operating activities</b>					
Profit after financial items	-10 084 674	-7 388 829	-17 894 817	-12 943 897	-29 086 533
Adjustments for items not included in cash flow etc	469 265	486 277	938 531	972 559	1 904 302
<b>Cash flow from operationg activities before changes in working capital</b>	<b>-9 615 409</b>	<b>-6 902 552</b>	<b>-16 956 286</b>	<b>-11 971 338</b>	<b>-27 182 231</b>
<b>Cash flow from changes in working capital</b>					
Change in inventory	3 080	320	-111 200	23 280	-260
Change in operating receivables	-1 991 291	452 334	-4 496 522	-822 390	-1 423 746
Change in operating liabilities	542 696	-1 839 405	1 226 061	1 452 711	912 855
<b>Cash flow from current operations</b>	<b>-11 060 923</b>	<b>-8 289 304</b>	<b>-20 337 947</b>	<b>-11 317 737</b>	<b>-27 693 382</b>
<b>Investment activities</b>					
Acquistion of intangibles	-	-	-	-	-
Acquisition of fixed assets	5 105	-	64 805	-	-
<b>Cash flow from investment activities</b>	<b>5 105</b>	<b>-</b>	<b>64 805</b>	<b>-</b>	<b>-</b>
<b>Financing activites</b>					
Paid-in option premium incl. bridge loan	20 679 115	-	20 679 115	-	19 252 938
Amortization	-100 000	-100 000	-200 000	-200 000	-400 000
<b>Cash flow from financing activities</b>	<b>20 579 115</b>	<b>-100 000</b>	<b>20 479 115</b>	<b>-200 000</b>	<b>18 852 939</b>
<b>Cash flow for the period</b>	<b>9 523 297</b>	<b>-8 189 304</b>	<b>205 973</b>	<b>-11 517 737</b>	<b>-8 840 443</b>
<b>Opening liquid funds</b>	<b>2 171 408</b>	<b>14 426 599</b>	<b>11 488 732</b>	<b>20 329 175</b>	<b>20 329 175</b>
<b>Closing liquid funds</b>	<b>11 694 704</b>	<b>8 811 439</b>	<b>11 694 704</b>	<b>8 811 439</b>	<b>11 488 732</b>

## Changes in equity

### 1 January 2022 – 31 December 2022

SEK	Share capital	Development fund	Share premium reserve	Accumulated profit/loss
Opening balance	905 325	18 566 363	130 452 900	-114 018 748
New share issue	466 244		22 104 639	
Expenses of the issue			-3 239 158	
Transfer to development fund		-1 856 636		1 856 636
Result for the period				-29 086 533
<b>Closing balance</b>	<b>1 371 569</b>	<b>16 709 727</b>	<b>149 318 381</b>	<b>-141 248 645</b>

### 1 January 2023 – 30 June 2023

SEK	Share capital	New share issues in progress	Development fund	Accumulated profit/loss
Opening balance	1 371 569	16 709 727	149 318 381	-141 248 645
New share issue	5 796 031		18 206 441	
Expenses of the issue			-3 323 357	
Transfer to development fund		-928 320		928 320
Result for the period				-17 894 817
<b>Closing balance</b>	<b>7 167 600</b>	<b>15 781 407</b>	<b>164 201 465</b>	<b>-158 215 142</b>

## General information

### Company information

Prostatype Genomics AB with organization number 556726-0285 is a limited company registered in Sweden, domiciled in Stockholm. The address is Gustaf III:s Boulevard, 169 73 Solna. The company is engaged in the research and developments of medical devices.

In this report, Prostatype Genomics AB is called either by its full name or as “the Company”. All figures in the report are in thousands of Swedish kronor (TSEK) if not otherwise specified.

The Company is the result of more than ten years of research into the genomics of prostate cancer. The Company was founded in 2007 as a spin off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market ready product Prostatype® Test System. Prostatype® is a test for diagnosis and prognosis that has been developed to provide the complementary information that is often needed for the selection of the optimal treatment strategy for each patient. The test analyzes the gene expression in cancer cells from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed. Aided by AI (Artificial Intelligence) technology, the gene test of Prostatype Genomics makes it possible to make a better prognosis and to classify the patient’s illness into different risk types. In that way the Company can reduce the risk of over- or under treatment, which in many cases lead to great discomfort for the patient. Prostatype® is today the only gene test for prostate cancer that is available in kit format. The product is also very scalable in terms of volume due to the algorithm that forms the basis of the test.

### Accounting principles

The report has been prepared in accordance with) BFNAR 2012:1 Årsredovisning och koncernredovisning (K3) issued by the Swedish Accounting Standards Boards (BFN). The accounting policy for the Company complies with applied accounting principles for the most recent published annual report.

### Related party transactions

During the period from January to June 30<sup>th</sup> 2023, except for what is detailed below, no related party transactions have taken place.

The Company has procured services for in total 209 TSEK from the company SecureAppbox AB during the period. SecureAppbox AB is a supplier of web-based solutions for P-score. Håkan Englund, Member of the Board of Prostatype Genomics AB, is the Chairman of the Board of SecureAppbox. Håkan Englund has not taken part in the procurement process for these services.

Transactions with related parties have been performed on market terms.

### Profit disposition

The Board is not intending to propose any dividend at the coming General Meeting.

### Risk factors

For a description of the most significant market- and operational risk, please see the recently published Annual Report for 2022.

## Other information

### Dates for publication of financial information

Q3 Report 2023-11-10

Q4 & Year-end Report 2024-02-15

This interim report, as well as further information, is available at Prostatype Genomics' web page, [www.prostatypegenomics.com](http://www.prostatypegenomics.com)

### Certified Advisor

Svensk Kapitalmarknadsgranskning AB, [www.skmg.se](http://www.skmg.se).

### Review of interim report

This interim report has not been subject to review by the Company's auditors.

### Publication

*This information is such information that Prostatype Genomics AB, from the time of listing, is obliged to publish in accordance with the EU market abuse regulation. The information is published by the below contact person, for publication on August 17, 2023, 8.00 AM. All information is given also in a Swedish version, and in case of any discrepancies, the Swedish version prevails.*

Fredrik Persson, VD, 073-049 77 01, [fredrik.persson@prostatypegenomics.com](mailto:fredrik.persson@prostatypegenomics.com)

The interim report provides a fair overview of the Company's operations, financial position and results.

Solna 17 August 2023

---

Anders Lundberg  
Chairman

---

Håkan Englund  
Director

---

Michael Häggman  
Director

---

Henrik Nilsson  
Director

---

Fredrik Persson  
CEO

---

Mattias Prage  
Director





**Prostatype Genomics AB**

Gustaf III:s Boulevard 34, SE-169 73  
Solna

Telefon:

+46 (0)8-20 87 00

Hemsida:

[www.prostatypegenomics.com](http://www.prostatypegenomics.com)